Conclusions
A meta-analysis of all three trials with 723 patients has been concluded, and is currently being submitted for publication. Our conclusions at this point are that the data are sufficiently compelling to suggest that active specific immunotherapy with an autologous tumor cell plus BCG vaccine should be considered as a standard therapy for patients with stage II colon cancer. A phase III trial in Stage III colon cancer comparing surgical resection followed by six months of 5-FU/leucovorin chemotherapy followed by a fourth vaccine boost at 6 months versus surgical resection alone, is being started in Europe and the United States.
This is a preview of subscription content, log in via an institution to check access.
References and Recommended Reading
Hanna MG Jr, Brandhorst JS, Peters LC: Active specific immunotherapy of residual metastasis: An evaluation of sources, doses, and ratios of BCG with tumor cells. Cancer Immunol Immunother 1979, 7:165–173.
Hanna MG Jr, Peters LC: Specific immunotherapy of established visceral micrometastases by BCG-tumor cell vaccine alone or as an adjunct to surgery. Cancer 1978, 42:2613–2625.
Hanna MG Jr, Pollack VA, Peters LC, et al.: Activespecific immunotherapy of established micrometastases with BCG plus tumor cell vaccines: Effective treatment of BCG side effects with isoniazid. Cancer 1982, 49:659–664.
Key ME, Hanna MG Jr: Mechanism of action of BCG-tumor cell vaccines in the generation of systemic tumor immunity. I. Synergism between BCG and line 10 tumor cells in the induction of an inflammatory response. J Natl Cancer Inst 1981, 67:853–861.
Peters LC, Brandhorst JS, Hanna MG Jr: Preparation of immunotherapeutic autologous tumor cell vaccines from solid tumors. Cancer Res 1979, 39:1353–1360.
Peters LC, Hanna MG Jr: Active-specific immunotherapy of established micrometastasis: Effect of cryopreservation procedures on tumor cell immunogenicity in guinea pigs. J Natl Cancer Inst 1980, 64:1521–1525.
Hoover HC Jr, Surdyke M, Dangel R, et al.: Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guérin vaccine. Cancer Res 1984, 44:1671–1676.
Hoover HC Jr, Brandhorst JS, Peters LC, et al.: Adjuvant active specific immunotherapy for human colorectal cancer: 6.5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 1993, 11:390–399.
Harris J, Ryan L, Hoover HC Jr, et al.: Delayed cutaneous hypersensitivity (DCH) as a measure of effectiveness for adjuvant active specific immunotherapy (ASI) in surgically resected stage II and III colon cancer: ECOG study E5283. Proc Am Soc Clin Oncol 1999, 18:438.
Vermorken JB, Claessen AME, van Tinteren H, et al.: Active specific immunotherapy for stage II and stage III human colon cancer: A randomised trial. Lancet 1999, 353:345–350.
Harrington DP: The tea leaves of small trials. J Clin Oncol 1999, 17:1336–1338.
The International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators: Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 1999, 17:1356–1363.
Mamounas E, Weiand S, Wolmark N, et al.: Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999, 17:1349–1355.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hoover, H.C., Hanna, M.G. Vaccine therapy for colon cancer. Curr Treat Options Gastro 2, 343–348 (1999). https://doi.org/10.1007/s11938-999-0023-4
Issue Date:
DOI: https://doi.org/10.1007/s11938-999-0023-4